<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588168</url>
  </required_header>
  <id_info>
    <org_study_id>2020-SR-252</org_study_id>
    <nct_id>NCT04588168</nct_id>
  </id_info>
  <brief_title>Multi-parameter Magnetic Resonance Imaging Guides Precise Treatment of Urothelial Carcinoma</brief_title>
  <official_title>Multi-parameter Magnetic Resonance Imaging for Early Evaluation of the Efficacy of Neoadjuvant Chemotherapy With Modified GC Regimen for Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose：To evaluate whether immediate multiparametric MRI evaluate the sensitivity of&#xD;
      modified neoadjuvant chemotherapy early in patient with muscle invasive bladder cancer（MIBC）.&#xD;
&#xD;
      Rationale：Multiparametric MRI may help detect the early changes of bladder cancer receiving&#xD;
      neoadjuvant chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective&#xD;
&#xD;
      Primary: To evaluate whether multiparametric MRI can determine the sensitivity of modified&#xD;
      neoadjuvant chemotherapy early in patient with muscle invasive bladder cancer（MIBC）.&#xD;
&#xD;
      Secondary：To determine whether multiparametric MRI can predict the prognosis of modified&#xD;
      neoadjuvant chemotherapy early in patient with muscle invasive bladder cancer.&#xD;
&#xD;
      Patients may receive neoadjuvant chemotherapy (typically three 21-day courses of modified&#xD;
      gemcitabine-cisplatin(GC) therapy) followed by radical cystectomy and lymph node dissection.&#xD;
&#xD;
      Patients with primary bladder cancer or recurrence which is confirmed by pathology of&#xD;
      previous biopsy or TURBT, undergo a multiparametric MRI(mpMRI) at baseline to stage the&#xD;
      primary tumor. The mpMRI includes T2-weighted MRI, diffusion-weighted imaging, and dynamic&#xD;
      contrast enhancement, which will be given a five-point VI-RADS（Vesical Imaging-Reporting And&#xD;
      Data System） score by two radiologists specialized in urogenital radiology. Patients&#xD;
      considered NMIBC（Non-muscle invasive bladder cancer） with mpMRI will be given TURBT, while&#xD;
      patients with MIBC（Muscle invasive bladder cancer）will receive radical cystectomy and lymph&#xD;
      node dissection after three 21-day courses of modified gemcitabine-cisplatin neoadjuvant&#xD;
      chemotherapy. Patients also undergo an immediate mpMRI scan after one, two, and three cycles&#xD;
      of neoadjuvant chemotherapy.&#xD;
&#xD;
      Specimens from the radical cystectomy are then examined by the pathology department as&#xD;
      standard routine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline tumor mp-MRI parameters at immediate mp-MRI evaluation.</measure>
    <time_frame>baseline, during the intervention (Within 24 hours after use of cisplatin of the first course of neoadjuvant chemotherapy(NAC), up to 2 weeks)</time_frame>
    <description>Using the built-in tools of the MRI imaging system to assess the changes of tumor size between immediate mp-MRI evaluation and baseline mp-MRI evaluation after the use of cisplatin during the first course of modified GC neoadjuvant chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline tumor mp-MRI parameters after two course of modified GC neoadjuvant chemotherapy.</measure>
    <time_frame>baseline, during the intervention(From the end date of the second course of NAC until one day before the third course of NAC, up to 7 weeks)</time_frame>
    <description>Using the built-in tools of the MRI imaging system to assess the changes of tumor size conventional mp-MRI evaluation and baseline mp-MRI evaluation after the second course of modified GC neoadjuvant chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline tumor mp-MRI parameters after three course of modified GC neoadjuvant chemotherapy.</measure>
    <time_frame>baseline, during the intervention(From the end date of the third course of NAC until one day before surgery, up to 10 weeks)</time_frame>
    <description>Using the built-in tools of the MRI imaging system to assess the changes of tumor size between conventional mp-MRI evaluation and baseline mp-MRI evaluation after the third course of modified GC neoadjuvant chemotherapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival.</measure>
    <time_frame>through study completion，an average of 3 year</time_frame>
    <description>Evaluate the overall survival of patients accept the modified GC neoadjuvant chemotherapy followed by radical cystectomy and lymphadenectomy.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental: Chemotherapy + mpMRI + surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline mpMRI /Neoadjuvant chemotherapy /Immediate mpMRI /Cystectomy and Lymphadenectomy / Postoperative pathology&#xD;
Drug: Chemotherapy Procedure: Immediate Multiparametric MRI Procedure: Cystectomy and Lymphadenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Chemotherapy + surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline mpMRI /Neoadjuvant chemotherapy /Cystectomy and Lymphadenectomy / Postoperative pathology&#xD;
Drug: Chemotherapy Procedure: Cystectomy and Lymphadenectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Patients with muscle invasive bladder cancer will receive modified gemcitabine-cisplatin neoadjuvant chemotherapy prior to radical cystectomy for a period of two months (three 21 day cycles) as part of standard clinical routine.</description>
    <arm_group_label>Experimental: Chemotherapy + mpMRI + surgery</arm_group_label>
    <arm_group_label>Experimental: Chemotherapy + surgery</arm_group_label>
    <other_name>Neoadjuvant chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Immediate Multiparametric MRI</intervention_name>
    <description>Within 24 hours after the use of cisplatin during the first course of modified GC neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive an immediate mpMRI scan.</description>
    <arm_group_label>Experimental: Chemotherapy + mpMRI + surgery</arm_group_label>
    <other_name>Multiparameter magnetic resonance imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cystectomy and Lymphadenectomy</intervention_name>
    <description>The patient with muscle invasive bladder cancer will undergo radical cystectomy and pelvic lymph node dissection followed by a urinary tract reconstruction.</description>
    <arm_group_label>Experimental: Chemotherapy + mpMRI + surgery</arm_group_label>
    <arm_group_label>Experimental: Chemotherapy + surgery</arm_group_label>
    <other_name>surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>conventional Multiparametric MRI</intervention_name>
    <description>After two and three course of neoadjuvant chemotherapy, patient considered muscle invasive bladder cancer with baseline mpMRI will receive a conventional mpMRI scan.</description>
    <arm_group_label>Experimental: Chemotherapy + mpMRI + surgery</arm_group_label>
    <arm_group_label>Experimental: Chemotherapy + surgery</arm_group_label>
    <other_name>Multiparameter magnetic resonance imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Baseline Multiparametric MRI</intervention_name>
    <description>Patient considered muscle invasive bladder cancer will receive a baseline mpMRI scan within one week before neoadjuvant chemotherapy.</description>
    <arm_group_label>Experimental: Chemotherapy + mpMRI + surgery</arm_group_label>
    <arm_group_label>Experimental: Chemotherapy + surgery</arm_group_label>
    <other_name>Multiparameter magnetic resonance imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically confirmed primary or recurrent bladder cancer.&#xD;
&#xD;
          -  Planned to undergo transurethral resection of bladder tumor (TURBT) or modified GC&#xD;
             regimen neoadjuvant chemotherapy plus radical total cystectomy.&#xD;
&#xD;
          -  18 years old and older.&#xD;
&#xD;
          -  Willing to give valid written informed consent.&#xD;
&#xD;
          -  No contraindications to the MRI(magnetic resonance imaging) and MRI contrast agent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal liver function (1.5 times higher than normal).&#xD;
&#xD;
          -  Glomerular filtration rate &lt; 60ml /min·kg.&#xD;
&#xD;
          -  Heart failure.&#xD;
&#xD;
          -  Acute myocardial infarction.&#xD;
&#xD;
          -  Severe heart and lung disease.&#xD;
&#xD;
          -  Hypotension and hypoxia.&#xD;
&#xD;
          -  Brain metastases, or other known central nervous system metastases.&#xD;
&#xD;
          -  A history of severe central nervous system diseases, including unexplained loss of&#xD;
             consciousness or transient ischemic attack.&#xD;
&#xD;
          -  Known congenital or acquired immunodeficiency, active hepatitis, active tuberculosis&#xD;
             and other active infections, etc.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Patients participating in other drug trials.&#xD;
&#xD;
          -  Patients with poor general condition (eg malnutrition, dehydration). Behavioral status&#xD;
             score (ZPS quintile) ≥ 2.&#xD;
&#xD;
          -  Patients with previous autoimmune diseases or existing autoimmune diseases. (including&#xD;
             controlled or uncontrolled drugs).&#xD;
&#xD;
          -  Patients undergoing organ transplantation (transplantation of liver, kidney, heart,&#xD;
             lung and other organs) or those who require long-term administration of&#xD;
             immunosuppressive agents due to personal conditions.&#xD;
&#xD;
          -  Those who are intolerant or allergic to cytotoxic chemotherapeutic drugs.&#xD;
&#xD;
          -  Bone marrow transplantation, severe leukopenia.&#xD;
&#xD;
          -  Patients with severe infection or trauma.&#xD;
&#xD;
          -  Any condition based on the investigation's clinical judgment that the patient is not&#xD;
             suitable for completing this study (such as not meeting the patient's most beneficial&#xD;
             treatment, patient compliance, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lv Qiang, MD，PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuan Baorui</last_name>
    <phone>+86 18351998926</phone>
    <email>yuanbr960720@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lv Qiang</last_name>
    <phone>+86 13505196501</phone>
    <email>doctorlvqiang@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Lu, PhD</last_name>
      <phone>13505196501</phone>
      <email>dxhlvqiang@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Pengchao Li, PhD</last_name>
      <phone>13584025756</phone>
      <email>superkulian@aliyun.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Raghavan D. Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder. Urol Oncol. 2003 Nov-Dec;21(6):468-74. Review.</citation>
    <PMID>14693275</PMID>
  </reference>
  <reference>
    <citation>Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001 Feb 1;19(3):666-75.</citation>
    <PMID>11157016</PMID>
  </reference>
  <reference>
    <citation>Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28;349(9):859-66. Erratum in: N Engl J Med. 2003 Nov 6;349(19):1880.</citation>
    <PMID>12944571</PMID>
  </reference>
  <reference>
    <citation>Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015 Aug 1;121(15):2586-93. doi: 10.1002/cncr.29387. Epub 2015 Apr 14.</citation>
    <PMID>25872978</PMID>
  </reference>
  <reference>
    <citation>International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group, Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011 Jun 1;29(16):2171-7. doi: 10.1200/JCO.2010.32.3139. Epub 2011 Apr 18.</citation>
    <PMID>21502557</PMID>
  </reference>
  <reference>
    <citation>Kim TJ, Cho KS, Koo KC. Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review. Cancers (Basel). 2020 Jan 13;12(1). pii: E192. doi: 10.3390/cancers12010192. Review.</citation>
    <PMID>31940998</PMID>
  </reference>
  <reference>
    <citation>Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, Fransen van de Putte EE, Horenblas S, Drabick JJ. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist. 2016 Jun;21(6):708-15. doi: 10.1634/theoncologist.2015-0440. Epub 2016 Apr 6. Review.</citation>
    <PMID>27053504</PMID>
  </reference>
  <reference>
    <citation>Bellmunt J, Mottet N, De Santis M. Urothelial carcinoma management in elderly or unfit patients. EJC Suppl. 2016 Mar;14(1):1-20. doi: 10.1016/j.ejcsup.2016.01.001. Epub 2016 Mar 22.</citation>
    <PMID>27358584</PMID>
  </reference>
  <reference>
    <citation>Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011 Mar;12(3):211-4. doi: 10.1016/S1470-2045(10)70275-8.</citation>
    <PMID>21376284</PMID>
  </reference>
  <reference>
    <citation>Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, Bochner BH. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006 Aug 1;107(3):506-13.</citation>
    <PMID>16773629</PMID>
  </reference>
  <reference>
    <citation>von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005 Jul 20;23(21):4602-8.</citation>
    <PMID>16034041</PMID>
  </reference>
  <reference>
    <citation>Hayashi N, Tochigi H, Shiraishi T, Takeda K, Kawamura J. A new staging criterion for bladder carcinoma using gadolinium-enhanced magnetic resonance imaging with an endorectal surface coil: a comparison with ultrasonography. BJU Int. 2000 Jan;85(1):32-6.</citation>
    <PMID>10619941</PMID>
  </reference>
  <reference>
    <citation>Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, Huddart R, Kennish S, Lerner S, Montironi R, Muglia VF, Salomon G, Thomas S, Vargas HA, Witjes JA, Takeuchi M, Barentsz J, Catto JWF. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018 Sep;74(3):294-306. doi: 10.1016/j.eururo.2018.04.029. Epub 2018 May 10. Review.</citation>
    <PMID>29755006</PMID>
  </reference>
  <reference>
    <citation>Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb;67(2):241-9. doi: 10.1016/j.eururo.2014.09.007. Epub 2014 Sep 23.</citation>
    <PMID>25257030</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiparametric Magnetic Resonance Imaging</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

